Aspyrian Therapeutics Inc., a San Diego-based biotechnology startup, has raised $8.45 million in equity financing, according to a recent filing with the Securities and Exchange Commission.

Aspyrian is focused on developing targeted therapies based on proprietary technology for cancer, pain and inflammation.

The company, founded in 2012, is using the near-infrared Photoimmunotherapy (PIT) platform exclusively licensed from the National Cancer Institute. PIT permits highly efficient and selective surgical removal of tumor cells while sparing damage to healthy organs adjacent to the tumor.